Karolinska Development's portfolio company OssDsign includes first patient to a clinical trial of the synthetic bone graft OssDsign Catalyst
September 09, 2021 02:00 ET | Karolinska Development AB (publ)
STOCKHOLM, SWEDEN – September 9, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company OssDsign AB has included the first patient to the clinical trial...
Karolinska Developments portföljbolag OssDsign inkluderar första patienten i en klinisk studie av det syntetiska bengraftet OssDsign Catalyst
September 09, 2021 02:00 ET | Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 9 september 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget OssDsign AB har inkluderat den första patienten till bolagets kliniska studie...
Interim Report - January-June 2021
August 19, 2021 02:00 ET | Karolinska Development AB (publ)
STOCKHOLM – 19 August 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-June 2021. The full report is available on the Company's website. “The...
Delårsrapport för januari – juni 2021
August 19, 2021 02:00 ET | Karolinska Development AB (publ)
STOCKHOLM – den 19 augusti 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari - juni 2021. Den fulla rapporten är tillgänglig på bolagets hemsida. ...
Karolinska Development's portfolio company OssDsign launches the synthetic bone graft OssDsign Catalyst on the U.S. market
August 16, 2021 09:51 ET | Karolinska Development AB (publ)
STOCKHOLM, SWEDEN – August 16, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company OssDsign AB has launched OssDsign Catalyst in the U.S. The product is...
Karolinska Developments portföljbolag OssDsign lanserar bengraftsubstitutet OssDsign Catalyst i USA
August 16, 2021 09:51 ET | Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 16 augusti 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att bolagets portföljbolag OssDsign AB har lanserat OssDsign Catalyst i USA. Produkten är ett...
Karolinska Development's portfolio company Aprea Therapeutics announces that FDA has issued a clinical hold on lymphoid malignancy program
August 12, 2021 10:21 ET | Karolinska Development AB (publ)
STOCKHOLM, SWEDEN – August 12, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the US Food and Drug Administration (FDA) has issued a clinical hold for Aprea Therapeutics...
Karolinska Developments portföljbolag Aprea Therapeutics meddelar att FDA beslutat om uppehåll i bolagets kliniska studieprogram
August 12, 2021 10:21 ET | Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 12 augusti 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att det amerikanska läkemedelsverket FDA har utfärdat ett clinical hold för portföljbolaget Aprea...
Karolinska Development’s portfolio company Aprea Therapeutics announces positive Phase 2 results for eprenetapopt
July 22, 2021 08:29 ET | Karolinska Development AB (publ)
STOCKHOLM SWEDEN – July 22, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Aprea Therapeutics has reported positive results from a Phase 2 trial...
Karolinska Developments portföljbolag Aprea Therapeutics rapporterar positiva fas 2-resultat för eprenetapopt
July 22, 2021 08:29 ET | Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 22 juli 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Aprea Therapeutics har rapporterat positiva resultat från en fas 2-studie av...